WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1997040033) INHIBITION OF THE BINDING OF HUMAN IGE TO ITS RECEPTOR BY TETRACYCLIC COMPOUNDS FOR THE ALLEVIATION OF IGE-MEDIATED IMMUNE RESPONSE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1997/040033    International Application No.:    PCT/US1997/006636
Publication Date: 30.10.1997 International Filing Date: 18.04.1997
Chapter 2 Demand Filed:    14.11.1997    
IPC:
A61K 31/352 (2006.01), A61K 31/4433 (2006.01), C07D 311/82 (2006.01)
Applicants: LEXIGEN PHARMACEUTICALS CORP. [US/US]; 125 Hartwell Avenue, Lexington, MA 02173 (US)
Inventors: CHENG, Y.-S., Edmond; (US).
LIU, Yuan; (US).
CHU, John; (US).
KINET, Jean-Pierre; (US).
JOUVIN, Marie-Helene; (US).
SUDO, Yukio; (JP).
QIAN, Xiuqi; (US)
Agent: HANLEY, Elizabeth, A.; Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109 (US)
Priority Data:
08/635,372 19.04.1996 US
08/698,243 15.08.1996 US
Title (EN) INHIBITION OF THE BINDING OF HUMAN IGE TO ITS RECEPTOR BY TETRACYCLIC COMPOUNDS FOR THE ALLEVIATION OF IGE-MEDIATED IMMUNE RESPONSE
(FR) INHIBITION DE LA LIAISON DE L'IGE HUMAINE A SON RECEPTEUR PAR DES COMPOSES TETRACYCLIQUES POUR L'ATTENUATION DE LA REACTION IMMUNITAIRE INDUITE PAR IGE
Abstract: front page image
(EN)Disclosed are chemical agents with unexpected activity to inhibit the interactions between human immunoglobulin E (IgE) and its receptor (Fc$g(e)RI) which interactions are known to be involved in triggering allergic responses. The agents may be used to modulate the allergic response in the treatment of various clinical conditions, including rhinitis, asthma, urticaria, atopic dermatitis, and anaphylactic shock. The agents can be formulated for oral, topical or parenteral administration.
(FR)Agents chimiques présentant une activité inattendue en ce qui concerne l'inhibition des interactions entre l'immunoglobuline E humaine (IgE) et son récepteur (Fc$g(e)RI), dont on sait qu'elles sont impliquées dans le déclenchement des réactions allergiques. Ces agents peuvent être utilisés pour moduler la réaction allergique dans le traitement de divers états cliniques, dont la rhinite, l'asthme, l'urticaire, l'eczéma constitutionnel et le choc anaphylactique. Ils peuvent être formulés de façon à être administrés par voie orale, topique ou parentérale.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU.
African Regional Intellectual Property Organization (GH, KE, LS, MW, SD, SZ, UG)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)